Treating rheumatic patients with a malignancy

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Elandt, Katarzyna ^a   Aletaha, Daniel ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALKYLATING AGENT; ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY;

BLADDER CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT REJECTION; HEALTH CARE QUALITY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MYOSITIS; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OBSERVATIONAL STUDY; ORGAN TRANSPLANTATION; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PROGNOSIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; IMMUNOLOGY; RISK FACTOR;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 79959745889     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3352     Document Type: Review

References (70)

1. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004, 96:709-711. 10.1093/jnci/djh118, 15126608.
2. Karagas MR, Cushing GL, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001, 85:683-686. 10.1054/bjoc.2001.1931, 2364134, 11531252.
3. Jensen A, Thomsen HF, Engebjerg MC, Olesen AB, Friis S, Karagas MR, Sorensen HT. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009, 100:200-205. 10.1038/sj.bjc.6604796, 2634665, 19034275.
4. Askling J, Klareskog L, Hjalgrim H, Baecklund E, Bjorkholm M, Ekbom A. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Ann Rheum Dis 2005, 64:1765-1768. 10.1136/ard.2005.036459, 1755302, 15843445.
5. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701. 10.1002/art.21675, 16508929.
6. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995, 54:708-712. 10.1136/ard.54.9.708, 1009984, 7495340.
7. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:1433-1439. 10.1002/art.22579, 17469100.
8. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 2006, 35:675-712. 10.1016/j.gtc.2006.07.003, 16952746.
9. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NK-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinase alpha and beta. Gastroenterology 2000, 119:1209-1218. 10.1053/gast.2000.19458, 11054378.
10. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
11. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Klareskog L. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1421-1426. 10.1136/ard.2004.033993, 1755244, 15829572.
12. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56:2886-2895. 10.1002/art.22864, 17729297.
13. Okada SK, Siegel JN. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006, 296:2201-2202.
14. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006, 54:1608-1618. 10.1002/art.21869, 16646004.
15. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2757-2764. 10.1002/art.22056, 16947774.
16. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006-1012. 10.1136/ard.2005.048371, 1798263, 16396977.
17. Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, Wallis WJ. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005, 141:861-864. 10.1001/archderm.141.7.861, 16027301.
18. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:670-675. 10.1136/ard.2006.062497, 1954627, 17158824.
19. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundstrom C, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Klareskog L, Feltelius N. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1414-1420. 10.1136/ard.2004.033241, 1755232, 15843454.
20. Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gomez-Reino JJ. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66:880-885. 10.1136/ard.2006.067660, 1955107, 17324968.
21. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699-703. 10.1136/ard.2004.030528, 1755491, 15695534.
22. Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006, 55:228-233. 10.1136/gut.2005.075937, 1856527, 16120759.
23. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007, 26:3699-3703. 10.1038/sj.onc.1210368, 17530023.
24. Lane L, Tamesis R, Rodriguez A, Christen W, Akova YA, Messmer E, Pedroza-Seres M, Barney N, Foster CS. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology 1995, 102:1530-1535.
25. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999, 29:148-158. 10.1016/S0049-0172(99)80026-2, 10622679.
26. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751. 10.1002/art.20311, 15188349.
27. Pedersen-Bjergaard J, Ersboll J, Hansen VL, Sorensen BL, Christoffersen K, Hou-Jensen K, Nissen NI, Knudsen JB, Hansen MM. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988, 318:1028-1032. 10.1056/NEJM198804213181604, 3352696.
28. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Kwoh CK. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995, 38:1120-1127. 10.1002/art.1780380815, 7639809.
29. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
30. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996, 124:477-484.
31. Patapanian H, Graham S, Sambrook PN, Browne CD, Champion GD, Cohen ML, Day RO. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol 1988, 27:44-47. 10.1093/rheumatology/27.1.44, 3422170.
32. van den Borne BE, Landewe RB, Houkes I. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998, 41:1930-1937. 10.1002/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N, 9811046.
33. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623-628. 10.1016/S0140-6736(97)08496-1, 9500317.
34. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4:222-230. 10.1046/j.1600-6143.2003.00325.x, 14974943.
35. McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. Clin Transpl 2000, 193-202.
36. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005, 80:1233-1243. 10.1097/01.tp.0000179639.98338.39, 16314791.
37. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001, 71:1065-1068. 10.1097/00007890-200104270-00010, 11374404.
38. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002, 16:1225-1232. 10.1046/j.1365-2036.2002.01297.x, 12144571.
39. Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 2005, 56:169-178. 10.1016/j.critrevonc.2005.02.004, 15979323.
40. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996, 46:1607-1612.
41. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249-1252. 10.1016/S0140-6736(94)92150-4, 7910274.
42. David KM, Morris JA, Steffen BJ, Chi-Burris KS, Gotz VP, Gordon RD. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005, 19:279-285. 10.1111/j.1399-0012.2005.00338.x, 15740568.
43. Wang K, Zhang H, Li Y, Wei Q, Li H, Yang Y, Lu Y. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004, 36:2068-2070. 10.1016/j.transproceed.2004.07.057, 15518748.
44. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25:1186-1191. 10.1016/j.healun.2006.06.010, 17045930.
45. Engl T, Makarević J, Relja B, Natsheh I, Müller I, Beecken WD, Jonas D, Blaheta RA. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005, 5:4. 10.1186/1471-2407-5-4, 545066, 15644133.
46. Vegso G, Sebestyen A, Paku S, Barna G, Hajdu M, Toth M, Jaray J, Kopper L. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 2007, 31:1003-1008. 10.1016/j.leukres.2006.12.019, 17320952.
47. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009, 125:1747-1754. 10.1002/ijc.24439, 19444916.
48. Luan F, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from anti-tumor efficacy. Transplantation 2002, 73:1565-1572. 10.1097/00007890-200205270-00008, 12042641.
49. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003, 63:917-926. 10.1046/j.1523-1755.2003.00805.x, 12631072.
50. Boffa DJ, Luan FL, Thomas D, Yang H, Sharma VK, Lagman M, Suthanthiran M. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004, 10:293-300. 10.1158/1078-0432.CCR-0629-3, 14734482.
51. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP. Influence of anti-tumor necrosis factor therapy on caner incidence in patients with rheumatoid arthritis who had a prior malignancy: results from British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010, 62:755-763.
52. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A. Risk of incidence or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in German biologics register RABBIT. Arthritis Res Ther 2010, 12:R5. 10.1186/ar2904, 2875631, 20064207.
53. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplantation 1997, 2:14-17.
54. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993, 55:742-747. 10.1097/00007890-199304000-00011, 8475546.
55. Snow AL, Martinez OM. Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant 2007, 7:271-277. 10.1111/j.1600-6143.2006.01650.x, 17229074.
56. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001, 33(Suppl 1):S38-S46.
57. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583-587. 2987704, 6142304.
58. York LJ, Qualtiere LF. Cyclosporin abrogates virus-specific T-cell control of EBV-induced B-cell lymphoproliferation. Viral Immunol 1990, 3:127-136. 10.1089/vim.1990.3.127, 2163257.
59. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005, 80(Suppl):S254-264. 10.1097/01.tp.0000186382.81130.ba, 16251858.
60. Penn I. Primary kidney tumors before and after renal transplantation. Transplantation 1995, 27:480-485.
61. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996, 2:52-59. 10.1002/lt.500020109, 9346628.
62. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007, 7:2587-2596. 10.1111/j.1600-6143.2007.01965.x, 17868066.
63. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I, . EUROCARE-4 Working Group Recent cancer survival in Europe: a period analysis 2000-2002 of the EUROCARE-4 data. Lancet Oncol 2007, 8:784-796. 10.1016/S1470-2045(07)70246-2, 17714993, EUROCARE-4 Working Group.
64. Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JWW, Santaquilani M, . EUROCARE Working Group Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783. 10.1016/S1470-2045(07)70245-0, 17714991, EUROCARE Working Group.
65. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
66. Loprinzi CL, DuVy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol 1993, 11:768-770.
67. Creamer P, Lim K, George E, Dieppe P. Acute inflammatory polyarthritis in association with tamoxifen. Br J Rheumatol 1994, 33:583-585. 10.1093/rheumatology/33.6.583, 8205409.
68. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981, 95:288-292.
69. Papamichael D, Amft N, Slevin ML, D'Cruz D. 5-Fluorouracil-induced Raynaud's phenomenon. Eur J Cancer 1998, 34:1983.
70. Swaneveld FH, van Vugt RM, de Boer JP, Dijkmans BA, Lems WF. A 57-yearold man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma. Clin Rheumatol 2008, 27:249-251. 10.1007/s10067-007-0704-0, 2262146, 17660934.